Literature DB >> 20690785

Effect of inadequate response to treatment in patients with depression.

Russell L Knoth1, Susan C Bolge, Edward Kim, Quynh-Van Tran.   

Abstract

OBJECTIVES: To assess the effects of inadequate response to antidepressant treatment on healthcare resource utilization and on work productivity in patients diagnosed as having major depressive disorder (MDD). STUDY
DESIGN: This study used data from the 2006 US National Health and Wellness Survey, a cross-sectional survey of adults 18 years and older.
METHODS: Patients who self-reported a confirmed diagnosis of depression and were currently taking antidepressant medication were included in the analyses. Adequacy of antidepressant treatment response was determined from responses to the mental health domain of the 8-Item Short Form Health Survey (SF-8). Logistic regression analyses adjusted for demographics, comorbidity, and component scores on the SF-8 were used to determine the associations between inadequacy of treatment response and health outcomes.
RESULTS: Of 5988 patients who met the inclusion criteria for the study, 30.9% were classified as antidepressant treatment responders, 31.2% were partial responders, and 37.9% were nonresponders. Partial response and nonresponse to treatment were associated with greater likelihood of emergency department utilization (odds ratios [ORs], 1.26 and 1.54, respectively; P <.01 for both) and hospitalization (OR, 1.23; P = .05 and OR, 1.39; P <.01, respectively). Similarly, partial response and nonresponse were associated with lower likelihood of current employment (OR, 0.83; P = .01 and OR, 0.63; P <.01, respectively) and with greater likelihood of work productivity loss among the employed (ORs, 1.42 and 1.99, respectively; P <.01 for both).
CONCLUSIONS: Patients with MDD who failed to respond to antidepressant treatment as evidenced by poor self-reported mental health status used more healthcare resources, were less likely to be employed, and had more work productivity loss than those who responded to antidepressant therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690785

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  16 in total

Review 1.  The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?

Authors:  David Petrik; Diane C Lagace; Amelia J Eisch
Journal:  Neuropharmacology       Date:  2011-09-19       Impact factor: 5.250

2.  Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder.

Authors:  Robert Riesenberg; Joshua Rosenthal; Leslie Moldauer; Christine Peterson
Journal:  Psychopharmacology (Berl)       Date:  2011-12-28       Impact factor: 4.530

3.  A community treatment intervention advancing active treatment in the elderly (ACTIVATE): a pilot study.

Authors:  Jo Anne Sirey; Charles P Hannon; Debra D'Angelo; Katherine Knies
Journal:  J Gerontol Soc Work       Date:  2012

4.  Resource utilization and costs associated with insomnia treatment in patients with major depressive disorder.

Authors:  Haijun Tian; Safiya Abouzaid; Susan Gabriel; Kristijan H Kahler; Edward Kim
Journal:  Prim Care Companion CNS Disord       Date:  2012-09-27

5.  Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.

Authors:  Emma Morton; Venkat Bhat; Peter Giacobbe; Wendy Lou; Erin E Michalak; Shane McInerney; Trisha Chakrabarty; Benicio N Frey; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam
Journal:  CNS Drugs       Date:  2021-04-16       Impact factor: 5.749

6.  Initial persistence with antihypertensive therapies is associated with depression treatment persistence, but not depression.

Authors:  Julie A Schmittdiel; Wendy Dyer; Connie Uratsu; David J Magid; Patrick J O'Connor; Arne Beck; Melissa Butler; Michael P Ho; Gabriela Vazquez-Benitez; Alyce S Adams
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-04-10       Impact factor: 3.738

7.  The impact of internet-based cognitive behavior therapy on work ability in patients with depression - a randomized controlled study.

Authors:  Dominique Hange; Nashmil Ariai; Marie Kivi; Maria Cm Eriksson; Shabnam Nejati; Eva-Lisa Petersson
Journal:  Int J Gen Med       Date:  2017-05-19

8.  Associations between antidepressant therapy, work ability, and sick leave for patients with common mental disorders within a two-year perspective - A longitudinal observational cohort study in Swedish primary care.

Authors:  Dominique Hange; Nashmil Ariai; Cecilia Björkelund; Irene Svenningsson; Shabnam Nejati; Eva-Lisa Petersson; Pia Augustsson; Ingmarie Skoglund
Journal:  Heliyon       Date:  2021-05-28

Review 9.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.

Authors:  Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett
Journal:  Clin Neurophysiol       Date:  2020-10-24       Impact factor: 4.861

Review 10.  Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies.

Authors:  Emmanuelle Weiller; Catherine Weiss; Christopher P Watling; Christopher Edge; Mary Hobart; Hans Eriksson; Maurizio Fava
Journal:  Neuropsychiatr Dis Treat       Date:  2017-12-29       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.